Press Room

Article / Jul 27, 2015

Hovione and Invion sign development agreement

Manufacturing Chemist, 27 July 2015

Hovione and Invion sign development agreement for first inhaled non-steroidal anti-inflammatory for asthma

Portuguese API manufacturer Hovione has agreed with Invion to progress the development of inhaled INV104 (zafirlukast) as a potential new treatment for asthma.

Hovione and the Australian drug developer will collaborate to develop the proprietary novel technology – a dry powder formulation of the compound INV104 (zafirlukast) delivered by Hovione’s inhaler.

 

Read the article here

Also in the Press Room

Press Release / Mar 07, 2018

Hovione sells the iMAX business

Hovione announces that it has concluded the sale of all of the share capital of iMAX Diagnostic Imaging limited.